Modern Medicine Feature Articles

Unlisted diagnosis codes could lead to denialsQ: We have recently been receiving patient complaints for procedure claim denials. These used to get paid, and our physicians haven’t changed how they are coding. Can you help?
MACRA plays blame game when patients don't adhereHow MACRA punishes physicians when patients don’t adhere
Supportive oncodermatologySkin side effects from anticancer treatments can be a special burden for patients already suffering the extreme pressures of a cancer diagnosis. Treatments must be customized for patients based on the type of cancer and treatment, as well as the patient’s personal goals. Close and active relationships with patients are vital to assure the best possible outcome.
Q&A: Diana Canto-Sims, OD, Owner, Buena Vista Optical, Wink and Save
Delaying the inevitablePracticing optometry takes place in many locales, with the majority free of barriers to practice.
Vaginal rejuvenation and the cosmetic practiceIt’s proving to be a viable addition to the scope of service in the cosmetic practice, but be forewarned: It’s serious business.
Marketing a new deviceDevice manufacturers are now offering marketing services to allay concerns that your new device is just going to gather dust, but do they really work?
Urothelial Ca immunotherapy approved for first-line use“Modern immunotherapy is active in advanced urothelial carcinoma and represents the most important advancement in the treatment of this disease in over 30 years,” says investigator Arjun V. Balar, MD.
Should RCC immunotherapy continue after progression?Some patients being treated with nivolumab (Opdivo) for advanced renal cell carcinoma may still derive benefit if continued on the immunotherapy after disease progression, according to an analysis of phase III study data.
Natural estrogen/progesterone HT capsule shows promiseA first-of-its-kind capsule combining natural 17β-estradiol and progesterone has promise for menopause-related hot flushes, according to results of a Phase 3 multi center trial.